Ligand ID: ASW


Drugbank ID:
DB00276
(Amsacrine)


Indication:
For treatment of acute myeloid leukaemia.

Get human targets for ASW in PDB (known and potential targets)

RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES MAPPED TO LIGAND 'ASW'

Click here for results that match SARS-Cov-2 / COVID-19 structures only
Click here for results that match SARS-related structures only


1) User may click on the DrReposER ID (the second column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera through AutoDock Vina.

DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 View Interface RMSD Seq.
Identity (%)		 HETATM Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		1z1j 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 6
PRO A 108
GLY A 174
ALA A 129
GLN A 192
1.37A17.92
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		2a5k 3C-LIKE PEPTIDASE
(SARSr-CoV)		4 / 6
PRO B 108
GLY B 174
ALA B 129
GLN B 192
1.36A18.02
None
None
None
AZP  B 307 ( 4.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		2acf REPLICASE
POLYPROTEIN 1AB
(SARS-COV
Tor2)		5 / 7
ILE B 205
PRO B 307
GLY B 279
ALA B 232
GLN B 320
1.78A11.93
None
None
None
GOL  B1004 (-3.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		2acf REPLICASE
POLYPROTEIN 1AB
(SARS-COV
Tor2)		4 / 6
PRO D 307
GLY D 230
ALA D 311
GLN D 244
1.48A11.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		2ahm REPLICASE
POLYPROTEIN 1AB,
HEAVY CHAIN
(SARSr-CoV)		4 / 7
ILE E 125
PRO E 126
ALA E 157
GLN E 163
1.10A13.93
None
GOL  E2001 (-4.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		2d2d 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 6
PRO B 108
GLY B 174
ALA B 129
GLN B 192
1.31A17.87
None
None
None
ENB  B1145 (-4.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		2dd8 IGG HEAVY CHAIN
IGG LIGHT CHAIN
(Homo
sapiens)		4 / 6
PRO H  52
GLY H  49
ALA H  78
GLN L  89
1.36A14.69
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		2fav REPLICASE
POLYPROTEIN 1AB
(PP1AB) (ORF1AB)
(SARSr-CoV)		5 / 7
ILE C  24
PRO C 126
GLY C  98
ALA C  51
GLN C 139
1.75A12.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		2fav REPLICASE
POLYPROTEIN 1AB
(PP1AB) (ORF1AB)
(SARSr-CoV)		4 / 6
PRO A 126
GLY A 131
ALA A  51
GLN B 120
1.26A12.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		2jw8 NUCLEOCAPSID PROTEIN
(SARSr-CoV)		4 / 6
PRO A 310
GLY A 336
ALA A 314
GLN A 282
1.53A9.02
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		2jzf REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		4 / 6
PRO A 519
ARG A 544
GLY A 577
ALA A 538
1.48A12.36
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		2ofz NUCLEOCAPSID PROTEIN
(SARS-COV
Tor2)		4 / 6
PRO A 118
ARG A  89
ALA A  51
GLN A  59
1.50A10.84
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		2ozk URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		4 / 6
PRO A  67
GLY A  76
ALA A  80
GLN A 187
1.49A18.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		2pwx 3C-LIKE PROTEINASE
(SARS-COV
BJ01)		4 / 6
PRO A 108
GLY A 174
ALA A 129
GLN A 192
1.34A17.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		2rhb URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		4 / 6
PRO A  67
GLY A  76
ALA A  80
GLN A 187
1.33A18.26
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		3d0g ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		4 / 6
ARG B 204
GLY B 205
ALA B 191
GLN B 221
1.45A21.41
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		3f9e 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 6
PRO A 108
GLY A 174
ALA A 129
GLN A 192
1.30A17.62
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		3iwm 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 6
PRO D 108
GLY D 174
ALA D 129
GLN D 192
1.21A17.92
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		3m3t 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 6
PRO A 108
GLY A 174
ALA A 129
GLN A 192
1.26A17.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		3to2 MHC CLASS I ANTIGEN
(Homo
sapiens)		4 / 7
ARG A 219
GLY A 221
GLU A 222
GLN A 255
1.19A15.03
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		3to2 MHC CLASS I ANTIGEN
(Homo
sapiens)		4 / 6
ARG A 219
GLY A 221
GLU A 222
GLN A 255
1.20A15.03
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		5f22 NSP8
(SARSr-CoV)		4 / 7
ILE B 125
PRO B 126
ALA B 157
GLN B 163
1.19A10.55
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		5tl6 REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		4 / 6
ARG B 139
GLY D 257
ALA B 142
GLN D 123
1.53A17.64
SO4  B 402 (-2.8A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		5x4r S PROTEIN
(MERS-CoV)		4 / 7
ILE A  48
PRO A  76
GLY A 255
GLN A  60
1.42A17.76
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		4 / 7
ILE A 995
GLY A 751
ALA A 998
GLN C 939
1.09A20.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		5x5b SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		4 / 6
PRO A 697
GLY B 867
ALA B 874
GLN B1018
1.40A20.96
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		5x5c S PROTEIN
(MERS-CoV)		4 / 6
PRO C  76
GLY C  73
ALA C 336
GLN A 819
1.48A20.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		5x5c S PROTEIN
(MERS-CoV)		4 / 7
ILE B1165
PRO B1167
GLY B 984
ALA C 962
1.11A20.83
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6acg SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 7
ILE C 696
PRO C 697
GLY B 873
GLN B 769
0.89A21.02
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6acg SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 6
PRO B1061
GLY B1075
ALA A 881
GLN B1088
1.36A21.02
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6crv SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		4 / 6
PRO C 697
GLY A 867
ALA A 874
GLN A1018
1.55A21.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6crv SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		4 / 7
ILE C 696
PRO C 697
GLY A 873
GLN A 769
1.14A21.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6crx SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		4 / 6
PRO C 697
GLY A 867
ALA A 874
GLN A1018
1.41A21.33
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6crx SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		4 / 7
ILE B 696
PRO B 697
GLY C 873
GLN C 769
0.94A21.33
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6m1d ACE2
(Homo
sapiens)		4 / 6
ARG B 393
GLY B 395
ALA B 386
GLN B  98
1.51A22.64
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 6
PRO A 108
GLY A 174
ALA A 129
GLN A 192
1.37A17.80
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 6
ARG B 131
GLY B 109
GLU B 240
GLN B 127
1.79A17.80
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6m3m NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 6
PRO C 118
ARG C  89
ALA C  51
GLN C  59
1.34A11.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6m71 NSP12
(SARS-CoV-2)		4 / 7
PRO A 537
GLY A 345
ALA A 379
GLN A 357
1.42A21.33
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6nb6 SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 7
ILE B 696
PRO B 697
GLY A 873
GLN A 769
1.15A21.20
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6nb7 SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 6
PRO C 697
GLY B 867
ALA B 874
GLN B1018
1.29A21.20
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6nur NSP8
(SARSr-CoV)		4 / 7
ILE D 120
PRO D 121
ALA D 152
GLN D 158
1.17A13.37
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 6
PRO B 715
GLY C 885
ALA C 892
GLN C1036
1.41A21.56
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
ILE C 896
PRO C 897
GLY B1131
ALA C 903
1.14A21.56
None
None
NAG  B1305 ( 4.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6vxs NSP3
(SARS-CoV-2)		4 / 6
PRO B 125
GLY B  48
ALA B 129
GLN B  62
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6vxs NSP3
(SARS-CoV-2)		4 / 7
PRO A 125
GLY A  48
ALA A 129
GLN A  62
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6vxs NSP3
(SARS-CoV-2)		4 / 6
PRO A 125
GLY A  47
ALA A 129
GLN A  62
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6vxs NSP3
(SARS-CoV-2)		4 / 7
PRO B 125
GLY B  48
ALA B 129
GLN B  62
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6vxs NSP3
(SARS-CoV-2)		4 / 6
PRO B 125
GLY B  47
ALA B 129
GLN B  62
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6vxs NSP3
(SARS-CoV-2)		4 / 6
PRO A 125
GLY A  48
ALA A 129
GLN A  62
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6vxs NSP3
(SARS-CoV-2)		4 / 7
ILE A  23
PRO A 125
GLY A 130
ALA A  50
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
ILE A1013
GLY A 769
ALA A1016
GLN C 957
1.15A21.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 6
PRO C 715
GLY C1046
ALA C1070
GLN C1036
1.47A21.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
ILE A 896
PRO A 897
GLY C1131
ALA A 903
1.16A21.44
None
None
NAG  C1310 (-3.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 6
PRO A 715
GLY B 885
ALA B 892
GLN B1036
1.37A21.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6vyo NUCLEOPROTEIN
(SARS-CoV-2)		4 / 6
PRO B 117
ARG B  88
ALA B  50
GLN B  58
1.46A10.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6w01 URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 6
PRO B  68
GLY B  77
ALA B  81
GLN B 188
1.46A18.68
None
PEG  B 411 ( 3.5A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6w41 CR3022 FAB HEAVY
CHAIN
CR3022 FAB LIGHT
CHAIN
(Homo
sapiens)		4 / 6
PRO H  52
GLY H  49
ALA H  78
GLN L  89
1.56A11.24
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6w41 CR3022 FAB HEAVY
CHAIN
(Homo
sapiens)		4 / 6
PRO H  52
GLY H  95
ALA H  78
GLN H   1
1.69A11.24
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6w41 CR3022 FAB HEAVY
CHAIN
(Homo
sapiens)		4 / 7
PRO H  52
GLY H  94
ALA H  78
GLN H   1
1.14A11.24
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6w41 CR3022 FAB HEAVY
CHAIN
CR3022 FAB LIGHT
CHAIN
(Homo
sapiens)		4 / 7
ILE H  69
GLY H 106
ALA H  78
GLN L  38
1.28A11.24
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6w41 CR3022 FAB HEAVY
CHAIN
(Homo
sapiens)		4 / 7
ILE H  69
GLY H 106
ALA H  78
GLN H  39
1.68A11.24
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6w41 CR3022 FAB HEAVY
CHAIN
(Homo
sapiens)		4 / 6
PRO H  52
GLY H  94
ALA H  78
GLN H   1
1.16A11.24
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6w41 CR3022 FAB HEAVY
CHAIN
(Homo
sapiens)		4 / 7
ILE H  51
GLY H 104
ALA H  78
GLN H   1
1.70A11.24
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6w61 NSP10
(SARS-CoV-2)		4 / 7
ILE B4352
PRO B4353
GLY B4380
ALA B4307
1.71A10.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 6
PRO A 108
GLY A 174
ALA A 129
GLN A 192
1.40A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6w6y NSP3
(SARS-CoV-2)		4 / 7
ILE A  23
PRO A 125
GLY A 130
ALA A  52
1.49A
AMP  A 201 ( 4.0A)
None
AMP  A 201 ( 3.5A)
AMP  A 201 ( 4.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6w6y NSP3
(SARS-CoV-2)		4 / 7
ILE A  23
PRO A 125
GLY A 130
ALA A  50
1.53A
AMP  A 201 ( 4.0A)
None
AMP  A 201 ( 3.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6w6y NSP3
(SARS-CoV-2)		4 / 7
ILE B  23
PRO B 125
GLY B  97
ALA B  50
1.51A
None
None
None
MES  B 201 ( 3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6w6y NSP3
(SARS-CoV-2)		4 / 7
PRO A 125
GLY A  47
ALA A 129
GLN A  62
1.80A10.06
None
None
AMP  A 201 ( 3.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6w6y NSP3
(SARS-CoV-2)		4 / 7
ILE A  23
PRO A 125
GLY A  97
ALA A  50
1.48A
AMP  A 201 ( 4.0A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6w6y NSP3
(SARS-CoV-2)		4 / 7
ILE A 106
PRO A  98
GLY A  79
GLN A 118
1.76A10.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6w6y NSP3
(SARS-CoV-2)		4 / 6
PRO B 125
GLY B  48
ALA B 129
GLN B  62
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6w6y NSP3
(SARS-CoV-2)		4 / 7
PRO B 125
GLY B  47
ALA B 129
GLN B  62
1.76A10.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6w6y NSP3
(SARS-CoV-2)		4 / 6
PRO B 125
GLY B  47
ALA B 129
GLN B  62
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6w6y NSP3
(SARS-CoV-2)		4 / 7
PRO A 125
GLY A  48
ALA A 129
GLN A  62
1.54A10.06
None
AMP  A 201 ( 3.6A)
AMP  A 201 ( 3.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6w6y NSP3
(SARS-CoV-2)		4 / 6
PRO A 125
GLY A  48
ALA A 129
GLN A  62
1.55A
None
AMP  A 201 ( 3.6A)
AMP  A 201 ( 3.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6w6y NSP3
(SARS-CoV-2)		4 / 7
PRO B 125
GLY B  48
ALA B 129
GLN B  62
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6w6y NSP3
(SARS-CoV-2)		4 / 7
ILE B  23
PRO B 125
GLY B 130
ALA B  52
1.47A
None
None
MES  B 201 ( 3.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6w6y NSP3
(SARS-CoV-2)		4 / 7
ILE B  23
PRO B 125
GLY B 130
ALA B  50
1.46A
None
None
MES  B 201 ( 3.4A)
MES  B 201 ( 3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6w6y NSP3
(SARS-CoV-2)		4 / 6
PRO A 125
GLY A  47
ALA A 129
GLN A  62
1.69A
None
None
AMP  A 201 ( 3.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 7
ILE C 151
GLY C 160
ALA C 149
GLN B 269
1.42A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6w9q 3C-LIKE PROTEINASE
PEPTIDE, NSP9 FUSION
(SARS-CoV-2)		4 / 7
ILE A  91
GLY A 100
ALA A  43
GLN A  -3
0.99A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6wcf NSP3
(SARS-CoV-2)		4 / 7
PRO A 125
GLY A  48
ALA A 129
GLN A  62
1.45A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6wcf NSP3
(SARS-CoV-2)		4 / 7
ILE A  23
PRO A 125
GLY A 130
ALA A  52
1.46A
None
None
MES  A 201 (-3.2A)
MES  A 202 (-4.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6wcf NSP3
(SARS-CoV-2)		4 / 7
ILE A  23
PRO A 125
GLY A  97
ALA A  50
1.49A
None
None
None
MES  A 201 ( 3.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6wcf NSP3
(SARS-CoV-2)		4 / 7
ILE A  23
PRO A 125
GLY A 130
ALA A  50
1.49A
None
None
MES  A 201 (-3.2A)
MES  A 201 ( 3.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6wcf NSP3
(SARS-CoV-2)		4 / 6
PRO A 125
GLY A  48
ALA A 129
GLN A  62
1.44A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6wcf NSP3
(SARS-CoV-2)		4 / 6
PRO A 125
GLY A  47
ALA A 129
GLN A  62
1.65A
None
MES  A 202 (-3.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6wen NSP3
(SARS-CoV-2)		4 / 6
PRO A 125
GLY A  47
ALA A 129
GLN A  62
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6wen NSP3
(SARS-CoV-2)		4 / 6
PRO A 125
GLY A  48
ALA A 129
GLN A  62
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6wen NSP3
(SARS-CoV-2)		4 / 7
ILE A  23
PRO A 125
GLY A  97
ALA A  50
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6wen NSP3
(SARS-CoV-2)		4 / 6
PRO A 125
GLY A  51
ALA A 129
GLN A  62
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6wen NSP3
(SARS-CoV-2)		4 / 7
ILE A  23
PRO A 125
GLY A 130
ALA A  50
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6wen NSP3
(SARS-CoV-2)		4 / 7
ILE A  23
PRO A 125
GLY A 130
ALA A  52
1.40A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6wey NSP3
(SARS-CoV-2)		4 / 6
PRO A 329
GLY A 251
ALA A 333
GLN A 266
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6wey NSP3
(SARS-CoV-2)		4 / 7
ILE A 227
PRO A 329
GLY A 301
ALA A 254
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6wey NSP3
(SARS-CoV-2)		4 / 6
PRO A 329
GLY A 252
ALA A 333
GLN A 266
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6wey NSP3
(SARS-CoV-2)		4 / 7
PRO A 329
GLY A 252
ALA A 333
GLN A 266
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6wiq NSP8
(SARS-CoV-2)		4 / 7
ILE B 120
PRO B 121
ALA B 152
GLN B 158
1.20A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 6
PRO B 309
GLY B 316
ALA A 308
GLN A 283
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 6
PRO A 309
GLY A 316
ALA B 308
GLN B 283
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 6
PRO E 309
GLY E 316
ALA F 308
GLN F 283
1.65A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 6
PRO F 309
GLY F 316
ALA E 308
GLN E 283
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 6
PRO C 309
GLY C 316
ALA D 308
GLN D 283
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 6
PRO D 309
GLY D 316
ALA C 308
GLN C 283
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 6
PRO C 309
GLY C 316
ALA D 308
GLN D 281
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 7
PRO B 117
ARG B  88
ALA B  50
GLN B  58
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 6
PRO B 117
ARG B  88
GLY B 129
GLN B  58
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 6
PRO D 117
ARG D  88
GLY D 129
GLN D  58
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 6
PRO C 117
ARG C  88
ALA C  50
GLN C  58
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 6
PRO C 117
ARG C  88
GLY C 129
GLN C  58
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 6
PRO A 117
ARG A  88
ALA A  50
GLN A  58
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 6
PRO D 117
ARG D  88
ALA D  50
GLN D  58
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 6
PRO A 117
ARG A  88
GLY A 129
GLN A  58
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 6
PRO B 117
ARG B  88
ALA B  50
GLN B  58
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 6
PRO A  68
GLY A  77
ALA A  81
GLN A 188
1.65A
None
EDO  A 406 ( 3.9A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 6
PRO D 125
GLY D  47
ALA D 129
GLN D  62
1.62A
None
APR  D 201 (-4.2A)
APR  D 201 (-3.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
PRO A 125
GLY A  48
ALA A 129
GLN A  62
1.49A
None
APR  A 201 (-3.5A)
APR  A 201 (-3.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
PRO D 125
GLY D  48
ALA D 129
GLN D  62
1.51A
None
APR  D 201 (-3.5A)
APR  D 201 (-3.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
PRO B 125
GLY B  48
ALA B 129
GLN B  62
1.53A
None
APR  B 201 (-3.4A)
APR  B 201 (-3.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
ILE D  23
PRO D 125
GLY D  97
ALA D  50
1.48A
APR  D 201 (-3.8A)
None
None
APR  D 201 ( 3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 6
PRO A 125
GLY A  48
ALA A 129
GLN A  62
1.52A
None
APR  A 201 (-3.5A)
APR  A 201 (-3.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 6
PRO C 125
GLY C  47
ALA C 129
GLN C  62
1.60A
None
APR  C 201 (-4.1A)
APR  C 201 (-3.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 6
PRO A 125
GLY A  47
ALA A 129
GLN A  62
1.58A
None
APR  A 201 (-4.1A)
APR  A 201 (-3.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
ILE D  23
PRO D 125
GLY D 130
ALA D  50
1.41A
APR  D 201 (-3.8A)
None
APR  D 201 (-3.2A)
APR  D 201 ( 3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
ILE C  23
PRO C 125
GLY C 130
ALA C  50
1.43A
APR  C 201 (-3.9A)
None
APR  C 201 (-3.0A)
APR  C 201 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
ILE A  23
PRO A 125
GLY A 130
ALA A  50
1.39A
APR  A 201 (-4.0A)
None
APR  A 201 (-3.5A)
APR  A 201 (-3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
ILE C  23
PRO C 125
GLY C  97
ALA C  50
1.50A
APR  C 201 (-3.9A)
None
None
APR  C 201 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
ILE D  23
PRO D 125
GLY D 130
ALA D  52
1.48A
APR  D 201 (-3.8A)
None
APR  D 201 (-3.2A)
APR  D 201 ( 4.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 6
PRO D 125
GLY D  48
ALA D 129
GLN D  62
1.55A
None
APR  D 201 (-3.5A)
APR  D 201 (-3.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
ILE B  23
PRO B 125
GLY B  97
ALA B  50
1.48A
APR  B 201 (-3.8A)
None
None
APR  B 201 (-3.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
ILE A  23
PRO A 125
GLY A 130
ALA A  52
1.49A
APR  A 201 (-4.0A)
None
APR  A 201 (-3.5A)
APR  A 201 ( 4.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
ILE C  23
PRO C 125
GLY C 130
ALA C  52
1.46A
APR  C 201 (-3.9A)
None
APR  C 201 (-3.0A)
APR  C 201 ( 4.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
ILE B  23
PRO B 125
GLY B 130
ALA B  52
1.48A
APR  B 201 (-3.8A)
None
APR  B 201 (-3.3A)
APR  B 201 ( 4.1A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
ILE B  23
PRO B 125
GLY B 130
ALA B  50
1.47A
APR  B 201 (-3.8A)
None
APR  B 201 (-3.3A)
APR  B 201 (-3.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 6
PRO B 125
GLY B  48
ALA B 129
GLN B  62
1.56A
None
APR  B 201 (-3.4A)
APR  B 201 (-3.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
PRO C 125
GLY C  48
ALA C 129
GLN C  62
1.51A
None
APR  C 201 (-3.5A)
APR  C 201 (-3.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 7
ILE A  23
PRO A 125
GLY A  97
ALA A  50
1.53A
APR  A 201 (-4.0A)
None
None
APR  A 201 (-3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 6
PRO C 125
GLY C  48
ALA C 129
GLN C  62
1.54A
None
APR  C 201 (-3.5A)
APR  C 201 (-3.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 6
PRO B 125
GLY B  47
ALA B 129
GLN B  62
1.61A
None
APR  B 201 (-4.0A)
APR  B 201 (-3.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6wqd NSP8
(SARS-CoV-2)		4 / 7
ILE D 120
PRO D 121
ALA D 152
GLN D 158
1.15A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6wqd NSP8
(SARS-CoV-2)		4 / 7
ILE B 120
PRO B 121
ALA B 152
GLN B 158
1.13A
None
None
EDO  B 302 ( 4.3A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6y2f REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 6
PRO A 108
GLY A 174
ALA A 129
GLN A 192
1.37A17.80
None
None
None
DMS  A 501 ( 3.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 6
PRO A 108
GLY A 174
ALA A 129
GLN A 192
1.34A10.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		4 / 7
ILE D 120
PRO D 121
ALA D 152
GLN D 158
1.16A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		4 / 7
ILE B 120
PRO B 121
ALA B 152
GLN B 158
1.36A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		4 / 7
ILE B  70
GLY B 112
ALA B  79
GLN C  44
1.30A
None
MLI  B 304 ( 4.8A)
None
1PE  C 301 (-3.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		4 / 7
ILE H  70
GLY H 112
ALA H  79
GLN L  44
1.26A
None
None
None
1PE  L1603 (-3.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6yla HEAVY CHAIN
(Homo
sapiens)		4 / 6
PRO H  53
GLY H  99
ALA H  79
GLN H   1
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		4 / 6
PRO B  53
GLY B  49
ALA B  79
GLN C  95
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6yla HEAVY CHAIN
(Homo
sapiens)		4 / 6
PRO B  53
GLY B  98
ALA B  79
GLN B   1
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6yla HEAVY CHAIN
(Homo
sapiens)		4 / 6
PRO B  53
GLY B  99
ALA B  79
GLN B   1
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6yla HEAVY CHAIN
(Homo
sapiens)		4 / 6
PRO H  53
GLY H  98
ALA H  79
GLN H   1
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		4 / 6
PRO B 153
GLY B  42
ALA B 172
GLN C  44
1.72A
None
1PE  C 301 (-4.6A)
None
1PE  C 301 (-3.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6yla HEAVY CHAIN
LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 7
ILE B  30
ALA A 372
GLU L  87
GLN B   3
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		4 / 6
PRO L  50
GLY H 112
ALA H  97
GLN B   6
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		4 / 6
PRO H  53
GLY H  49
ALA H  79
GLN L  95
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		4 / 6
PRO C  50
GLY B 112
ALA B  97
GLN H   6
1.63A
None
MLI  B 304 ( 4.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ym0 LIGHT CHAIN
(Homo
sapiens)		4 / 7
ILE L 112
ALA L  12
GLU L 111
GLN L  44
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ym0 HEAVY CHAIN
(Homo
sapiens)		4 / 6
PRO H  53
GLY H  98
ALA H  79
GLN H   1
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ym0 HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		4 / 6
PRO H  53
GLY H  49
ALA H  79
GLN L  95
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ym0 HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		4 / 7
ILE H  70
GLY H 112
ALA H  79
GLN L  44
1.20A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 6
ARG A 131
GLY A 109
GLU A 240
GLN A 127
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6yor IGG H CHAIN
IGG L CHAIN
(Homo
sapiens)		4 / 6
PRO B  53
GLY B  49
ALA B  79
GLN C  95
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6yor IGG H CHAIN
(Homo
sapiens)		4 / 6
PRO B  53
GLY B  99
ALA B  79
GLN B   1
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6yor IGG H CHAIN
(Homo
sapiens)		4 / 6
PRO H  53
GLY H  98
ALA H  79
GLN H   1
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6yor IGG H CHAIN
(Homo
sapiens)		4 / 6
PRO B  53
GLY B  98
ALA B  79
GLN B   1
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6yor IGG H CHAIN
(Homo
sapiens)		4 / 6
PRO H  53
GLY H  99
ALA H  79
GLN H   1
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6yor IGG H CHAIN
IGG L CHAIN
(Homo
sapiens)		4 / 6
PRO H  53
GLY H  49
ALA H  79
GLN L  95
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6yor IGG H CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 7
ILE E 410
GLY E 504
ALA E 435
GLN B  82
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6yor IGG H CHAIN
IGG L CHAIN
(Homo
sapiens)		4 / 7
ILE H  70
GLY H 112
ALA H  79
GLN L  44
1.26A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6yor IGG H CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 7
ILE A 410
GLY A 504
ALA A 435
GLN H  82
1.42A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6yor IGG H CHAIN
IGG L CHAIN
(Homo
sapiens)		4 / 7
ILE B  70
GLY B 112
ALA B  79
GLN C  44
1.26A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 6
PRO A 108
GLY A 174
ALA A 129
GLN A 192
1.38A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE C  23
PRO C 125
GLY C 130
ALA C  50
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE C  23
PRO C 125
GLY C 130
ALA C  52
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE E  23
PRO E 125
GLY E 130
ALA E  50
1.46A
EDO  E 205 (-4.2A)
None
EPE  E 202 ( 4.5A)
EPE  E 202 (-3.1A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE A  23
PRO A 125
GLY A 130
ALA A  52
1.50A
None
None
EDO  A 202 ( 4.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
PRO D 125
GLY D  48
ALA D 129
GLN D  62
1.50A
None
EDO  D 209 ( 4.7A)
EDO  D 205 (-4.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO B 125
GLY B  48
ALA B 129
GLN B  62
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE C  23
PRO C 125
GLY C  97
ALA C  50
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
PRO E 125
GLY E  48
ALA E 129
GLN E  62
1.47A
None
EPE  E 202 ( 4.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE D  23
PRO D 125
GLY D 130
ALA D  50
1.47A
EDO  D 208 (-4.0A)
None
EDO  D 205 ( 4.9A)
EDO  D 206 (-3.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO C 125
GLY C  47
ALA C 129
GLN C  62
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE E  23
PRO E 125
GLY E 130
ALA E  52
1.50A
EDO  E 205 (-4.2A)
None
EPE  E 202 ( 4.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE B  23
PRO B 125
GLY B  97
ALA B  50
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO A 125
GLY A  47
ALA A 129
GLN A  62
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO A 125
GLY A  97
ALA A 129
GLN D 118
1.76A
None
EDO  A 202 ( 4.9A)
None
EDO  D 201 ( 4.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE B  23
PRO B 125
GLY B 130
ALA B  50
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE B  23
PRO B 125
GLY B 130
ALA B  52
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
PRO C 125
GLY C  48
ALA C 129
GLN C  62
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO E 125
GLY E  48
ALA E 129
GLN E  62
1.47A
None
EPE  E 202 ( 4.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE D  23
PRO D 125
GLY D  97
ALA D  50
1.47A
EDO  D 208 (-4.0A)
None
None
EDO  D 206 (-3.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO D 125
GLY D  97
ALA D 129
GLN A 118
1.68A
None
None
EDO  D 205 (-4.5A)
EDO  D 201 ( 4.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO C 125
GLY C  48
ALA C 129
GLN C  62
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO A 125
GLY A  48
ALA A 129
GLN A  62
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO D 125
GLY D  48
ALA D 129
GLN D  62
1.49A
None
EDO  D 209 ( 4.7A)
EDO  D 205 (-4.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE A  23
PRO A 125
GLY A 130
ALA A  50
1.47A
None
None
EDO  A 202 ( 4.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO E 125
GLY E  47
ALA E 129
GLN E  62
1.65A
None
EPE  E 202 (-4.3A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE A  23
PRO A 125
GLY A  97
ALA A  50
1.53A
None
None
EDO  A 202 ( 4.9A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO D 125
GLY D  47
ALA D 129
GLN D  62
1.71A
None
EDO  D 206 (-4.5A)
EDO  D 205 (-4.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
PRO B 125
GLY B  48
ALA B 129
GLN B  62
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO B 125
GLY B  47
ALA B 129
GLN B  62
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
PRO A 125
GLY A  48
ALA A 129
GLN A  62
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO D 125
GLY D  48
ALA D 129
GLN D  62
1.52A
None
EDO  D 204 ( 3.4A)
APR  D 201 (-3.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO A 125
GLY A  97
ALA A 129
GLN D 118
1.59A
None
None
APR  A 201 ( 3.7A)
EDO  A 207 ( 4.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO A 125
GLY A  47
ALA A 129
GLN A  62
1.62A
None
APR  A 201 (-4.1A)
APR  A 201 ( 3.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO E 125
GLY E  48
ALA E 129
GLN E  62
1.51A
None
APR  E 201 (-3.4A)
APR  E 201 (-3.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO D 125
GLY D  97
ALA D 129
GLN A 118
1.57A
None
None
APR  D 201 (-3.4A)
EDO  D 203 (-3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE A  23
PRO A 125
GLY A  97
ALA A  50
1.48A
APR  A 201 (-3.9A)
None
None
APR  A 201 (-3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO B 125
GLY B  48
ALA B 129
GLN B  62
1.53A
None
APR  B 201 (-3.5A)
APR  B 201 (-3.6A)
EDO  B 202 (-4.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE B  23
PRO B 125
GLY B 130
ALA B  52
1.53A
APR  B 201 (-4.1A)
None
APR  B 201 (-3.2A)
APR  B 201 ( 4.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
PRO A 125
GLY A  48
ALA A 129
GLN A  62
1.51A
None
APR  A 201 (-3.4A)
APR  A 201 ( 3.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO C 125
GLY C  47
ALA C 129
GLN C  62
1.67A
None
APR  C 201 (-4.3A)
APR  C 201 (-3.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE D  23
PRO D 125
GLY D 130
ALA D  50
1.45A
APR  D 201 (-3.9A)
None
APR  D 201 (-3.2A)
APR  D 201 (-3.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE B  23
PRO B 125
GLY B  97
ALA B  50
1.50A
APR  B 201 (-4.1A)
None
None
APR  B 201 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE D  23
PRO D 125
GLY D  97
ALA D  50
1.47A
APR  D 201 (-3.9A)
None
None
APR  D 201 (-3.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
PRO C 125
GLY C  48
ALA C 129
GLN C  62
1.50A
None
APR  C 201 (-3.5A)
APR  C 201 (-3.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE E  23
PRO E 125
GLY E 130
ALA E  52
1.53A
APR  E 201 (-4.1A)
None
APR  E 201 (-3.2A)
APR  E 201 ( 4.1A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE E  23
PRO E 125
GLY E 130
ALA E  50
1.44A
APR  E 201 (-4.1A)
None
APR  E 201 (-3.2A)
APR  E 201 (-3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO D 125
GLY D  47
ALA D 129
GLN D  62
1.67A
None
APR  D 201 ( 4.3A)
APR  D 201 (-3.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE C  23
PRO C 125
GLY C 130
ALA C  50
1.45A
APR  C 201 (-3.9A)
None
APR  C 201 (-3.2A)
APR  C 201 (-3.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE A  23
PRO A 125
GLY A 130
ALA A  50
1.45A
APR  A 201 (-3.9A)
None
APR  A 201 ( 3.2A)
APR  A 201 (-3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE E  23
PRO E 125
GLY E  97
ALA E  50
1.50A
APR  E 201 (-4.1A)
None
None
APR  E 201 (-3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO A 125
GLY A  48
ALA A 129
GLN A  62
1.54A
None
APR  A 201 (-3.4A)
APR  A 201 ( 3.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
PRO D 125
GLY D  48
ALA D 129
GLN D  62
1.50A
None
EDO  D 204 ( 3.4A)
APR  D 201 (-3.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO B 125
GLY B  47
ALA B 129
GLN B  62
1.64A
None
APR  B 201 (-3.6A)
APR  B 201 (-3.6A)
EDO  B 202 (-4.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE C  23
PRO C 125
GLY C  97
ALA C  50
1.48A
APR  C 201 (-3.9A)
None
None
APR  C 201 (-3.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO C 125
GLY C  48
ALA C 129
GLN C  62
1.53A
None
APR  C 201 (-3.5A)
APR  C 201 (-3.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE B  23
PRO B 125
GLY B 130
ALA B  50
1.45A
APR  B 201 (-4.1A)
None
APR  B 201 (-3.2A)
APR  B 201 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
PRO B 125
GLY B  48
ALA B 129
GLN B  62
1.51A
None
APR  B 201 (-3.5A)
APR  B 201 (-3.6A)
EDO  B 202 (-4.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO E 125
GLY E  47
ALA E 129
GLN E  62
1.64A
None
APR  E 201 (-4.4A)
APR  E 201 (-3.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
PRO E 125
GLY E  48
ALA E 129
GLN E  62
1.49A
None
APR  E 201 (-3.4A)
APR  E 201 (-3.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO B 125
GLY B  48
ALA B 129
GLN B  62
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
PRO A 125
GLY A  48
ALA A 129
GLN A  62
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE B  23
PRO B 125
GLY B 130
ALA B  52
1.51A
EDO  B 202 (-4.0A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE C  23
PRO C 125
GLY C  97
ALA C  50
1.45A
EDO  C 206 (-4.1A)
None
None
MES  C 201 ( 3.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO A 125
GLY A  97
ALA A 129
GLN C 118
1.63A
None
None
None
EDO  A 204 (-4.1A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO A 125
GLY A  48
ALA A 129
GLN A  62
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
PRO B 125
GLY B  48
ALA B 129
GLN B  62
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO C 125
GLY C  48
ALA C 129
GLN C  62
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO B 125
GLY B  47
ALA B 129
GLN B  62
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE A  23
PRO A 125
GLY A  97
ALA A  50
1.52A
None
None
None
MES  A 201 ( 3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE B  23
PRO B 125
GLY B  97
ALA B  50
1.50A
EDO  B 202 (-4.0A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE A  23
PRO A 125
GLY A 130
ALA A  52
1.48A
None
None
MES  A 201 (-3.1A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE A  23
PRO A 125
GLY A 130
ALA A  50
1.49A
None
None
MES  A 201 (-3.1A)
MES  A 201 ( 3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
ILE B  23
PRO B 125
GLY B 130
ALA B  50
1.51A
EDO  B 202 (-4.0A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 7
PRO C 125
GLY C  48
ALA C 129
GLN C  62
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_F_ASWF101_1
(DNA TOPOISOMERASE
2-BETA)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 6
PRO A 125
GLY A  47
ALA A 129
GLN A  62
1.68A
None
MES  A 201 ( 4.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		7bv1 NSP8
(SARS-CoV-2)		4 / 7
ILE D 120
PRO D 121
ALA D 152
GLN D 158
1.37A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4G0U_B_ASWB1301_1
(DNA TOPOISOMERASE
2-BETA)		7bv2 NSP12
(SARS-CoV-2)		4 / 7
PRO A 537
GLY A 345
ALA A 379
GLN A 357
1.45A
None